Biosyent's total assets for Q2 2025 were C$43.50M, an increase of 1.71% from the previous quarter. TSE:RX total liabilities were C$5.89M for the fiscal quarter, a -12.68% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.